Communiqués Appili Therapeutics Inc.

Actions

APLI

CA03783R1073

Marché Fermé - Toronto S.E. Autres places de cotation 21:18:21 04/07/2024			Varia. 5j.	Varia. 1 janv.
0,04 ^CAD	0,00%		0,00%	+14,29%

26/06	Appili Therapeutics réduit sa perte au quatrième trimestre en raison de l'augmentation de l'aide gouvernementale	MT
26/06	Appili Therapeutics Inc. annonce ses résultats pour l'exercice clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results	25/06	AQ
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	03/04	AQ
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	03/04	AQ
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks	12/03	AQ
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024	13/02	AQ
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan	18/12	AQ
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan	15/12	BU
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024	13/11	BU
Appili Therapeutics Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy	26/10/23	AQ
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy	25/10/23	BU
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update	28/09/23	BU
Appili Therapeutics Presents at the 10th International Tularemia Conference	27/09/23	BU
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ Metronidazole Oral Suspension	26/09/23	AQ
OTC Stocks On The Run Watchlist (SWISF, NHMD, APLIF, ASRE)	26/09/23	AQ
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension	25/09/23	BU
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024	14/08/23	AQ
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024	11/08/23	BU
Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.	30/06/23	AQ
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results	26/06/23	AQ
Appili Therapeutics – Press Release Correction	23/06/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Appili Therapeutics Inc.

Actions

APLI

CA03783R1073

Communiqués

Filtres